Movement disorders clinical practice · 2024
A 4-Year Follow-Up of Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Parkinson's Disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Öthman Mezin, Nyholm Dag
Аннотация
BACKGROUND: Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion was introduced to the Swedish market in 2019 for Parkinson's disease (PD) with motor fluctuations. Long-term data are lacking.
OBJECTIVES: To study long-term data on LECIG treatment.
METHODS: A retrospective analysis of the first 24 patients receiving LECIG in Sweden from 2019 to 2023.
RESULTS: Five of 24 (21%) patients discontinued LECIG because of side effects, mostly diarrhea. Eight of the 24 (33%) patients died while receiving LECIG. Eleven of 24 (46%) patients were still on LECIG. Median (range) for disease and treatment duration was 19 (9-30) and 3.6 (3.1-4.0) years, respectively, whereas health-related quality of life scales showed median (interquartile range; n) Parkinson's Disease Questionnaire 8-item summary index scores of 38 (4; n = 7), EuroQol 5D scores of 0.59 (0.17; n = 7), and EQ-5D visual analogue scale scores of 65 (10; n = 7).
CONCLUSIONS: LECIG infusion is a viable treatment option for PD patients with motor fluctuations, for up to 4 years in our cohort.
OBJECTIVES: To study long-term data on LECIG treatment.
METHODS: A retrospective analysis of the first 24 patients receiving LECIG in Sweden from 2019 to 2023.
RESULTS: Five of 24 (21%) patients discontinued LECIG because of side effects, mostly diarrhea. Eight of the 24 (33%) patients died while receiving LECIG. Eleven of 24 (46%) patients were still on LECIG. Median (range) for disease and treatment duration was 19 (9-30) and 3.6 (3.1-4.0) years, respectively, whereas health-related quality of life scales showed median (interquartile range; n) Parkinson's Disease Questionnaire 8-item summary index scores of 38 (4; n = 7), EuroQol 5D scores of 0.59 (0.17; n = 7), and EQ-5D visual analogue scale scores of 65 (10; n = 7).
CONCLUSIONS: LECIG infusion is a viable treatment option for PD patients with motor fluctuations, for up to 4 years in our cohort.